HC Wainwright & Co. analyst Robert Burns upgrades Cardiff Oncology (NASDAQ:CRDF) from Neutral

SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CR

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stag

Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday&#39

Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.14) per share which beat the analyst

Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onv

Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday&#3

Dow gains over 150 points, NASDAQ and S&P 500 also up. Consumer discretionary shares jump 1.2%,

US stocks traded higher with Dow up 150 points. Consumer discretionary shares surged 1.3% while heal

Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (the “Company”),

Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line

Craig-Hallum analyst Albert Lowe downgrades Cardiff Oncology (NASDAQ:CRDF) from Buy to Hold and l

Data Highlights from the ongoing Phase 2 trial (Data cut: March 18, 2026):In the intent-to-treat (IT

-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + s

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage

Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Resident

Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; i

Cardiff Oncology Inc. (NASDAQ:CRDF) on Tuesday said that it filed a lawsuit against Nerviano Medical

Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemother

SAN DIEGO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clini

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stag

SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stag

Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, inc

Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive Officer Appoint

Cardiff Oncology posted Phase II data for onvansertib in RAS-mutated mCRC, showing a 72% ORR versus

Cardiff Oncology, Inc. (CRDF) Discusses Advances in First-Line Treatment for RAS-Mutated Metastatic

SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stag

Preclinical results in therapy-resistant HER2-low breast cancer models demonstrate enhanced antitumo

BioStem Technologies (OTCMKTS:BSEM - Get Free Report) and Cardiff Oncology (NASDAQ: CRDF - Get Free

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-q

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly ear

Gainers

Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) rose 41.7% to $2.72 in pre-market trad

  On Wednesday, 807 companies reached new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.

  Wednesday's session saw 784 companies set new 52-week lows.

  During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week

  On Friday, 431 companies hit new 52-week lows.

    On Thursday, 236 companies hit new 52-week lows.